Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05180474 2026-04-13

GEN1047 for Solid Tumors - First in Human (FIH) Trial

Phase 1/2 Terminated

179 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05538897 2026-04-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Phase 1/2 Active not recruiting

96 enrolled

Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

NCT05739981 2026-04-13

MRD

Phase 1/2 Recruiting

30 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07523529 2026-04-13

SELECT-2CAR

Phase 1/2 Recruiting

72 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologic

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05919264 2026-04-09

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

595 enrolled

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT06253494 2026-04-09

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Phase 1/2 Recruiting

60 enrolled

Gynecologic

Endometrial Neoplasms

NCT06188520 2026-04-08

CYCAD-1

Phase 1/2 Recruiting

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT07262619 2026-04-08

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Phase 1/2 Recruiting

160 enrolled

Gynecologic

Turcot syndrome, Neoplasm Metastasis, Endometrial Neoplasms

NCT05579366 2026-04-07

RAINFOL-01

Phase 1/2 Recruiting

764 enrolled

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02830724 2026-04-06

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Phase 1/2 Recruiting

124 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04708470 2026-04-06

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Phase 1/2 Active not recruiting

55 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT04938583 2026-04-06

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

54 enrolled

Gynecologic

Ovarian Neoplasms

NCT05920798 2026-04-06

FRAPPE

Phase 1/2 Recruiting

40 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07060365 2026-04-03

A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

Phase 1/2 Withdrawn

Gynecologic

Ovarian Neoplasms

NCT04486352 2026-04-01

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Gynecologic

Endometrial Neoplasms

NCT05735080 2026-04-01

INX-315-01

Phase 1/2 Recruiting

150 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT06888921 2026-04-01

MAIA-ovarian

Phase 1/2 Recruiting

60 enrolled

Gynecologic

Ovarian Neoplasms

NCT06395519 2026-03-27

ERADIC8

Phase 1/2 Recruiting

120 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06843447 2026-03-27

MK-5909-003

Phase 1/2 Recruiting

280 enrolled

Gynecologic

Ovarian Cancer Recurrent

NCT07189871 2026-03-27

BetaBart

Phase 1/2 Recruiting

61 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07432633 2026-03-27

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Phase 1/2 Recruiting

71 enrolled

GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Lobular

Clinical Trials

ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

MEDIOLA

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

OCTOPOD

OVATION 2

ACTengine

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

GEN1047 for Solid Tumors - First in Human (FIH) Trial

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

MRD

SELECT-2CAR

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

CYCAD-1

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

RAINFOL-01

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

FRAPPE

A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

EndoMAP

INX-315-01

MAIA-ovarian

ERADIC8

MK-5909-003

BetaBart

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications